News

Catalent Pharma Solutions is opening a gateway to China for its clinical-trial supplies business through a joint venture with locally based contract research organisation ShangPharma Corporation.

Incentives to encourage the pharmaceutical industry to develop new antibiotics must be put in place, and fast, or in just 20 years minor operations could be fatal, chief medical officer Dame Sally Davies has warned.

In a move which appears at odds with a push for transparency within the pharmaceutical industry, AbbVie is suing the European Medicines Agency to prevent it from releasing data related to its blockbuster Humira.

Days after US regulators turned down their bid to expand the label on Xarelto to include the reduction of the risk of cardiovascular events in acute coronary syndrome patients, Bayer and Johnson & Johnson have unveiled a number of studies designed to look at other indications for the bloodthinner.

The pharmaceutical industry is in the midst of a new era of next-generation high-throughput screening which will drive a significant improvement in R&D productivity, according to a report published by broker Liberum Capital.

Just 25% of local authorities are aware of how many people are living with hepatitis C in their areas, a damning new report by the Hepatitis C Trust has revealed.

A single dose of the investigational anti-inflammatory inclacumab, developed by Roche and Genmab,  considerably reduces damage to heart muscle during angioplasty.

Galapagos have suffered a setback with partner Roche ending a partnership with the Belgian biotech which focused on fibrosis.

The Prescription Charges Coalition* is putting pressure on the government to make patients with long-term medical conditions exempt from paying, after finding a “shocking lack of fairness” across the current system.

Takeda Pharmaceutical Co has filed vedolizumab, its investigational, gut-selective monoclonal antibody, in Europe for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease.

Cutting-edge synthetic biology companies have received a £5.3 million government cash injection as the UK looks to boost the bioscience sector.

An influential GP has said that the government’s new drug pricing scheme is merely “a sound bite” that nobody understands.

Eisai has expressed its outrage at the German reimbursement regulatory body’s ruling that the benefits of the Japan-headquartered firm’s first-in-class antiepileptic Fycompa are unproven.

The European Commission says that an inverted triangle will shortly appear on the inside leaflet of certain drugs “to easily identify medicinal products that are undergoing additional monitoring”.

GlaxoSmithKline has announced the submission of a marketing authorisation application for albiglutide, which will have the brand name Eperzan, to the European Medicines Agency.